Currently, only seven clinical trials examining the usage of CAR T cells for the treatment of melanoma, targeting among others disialoganglioside GD2 or vascular endothelial growth factor receptor 2 (VEGFR2), are on-going, while no clinical trials have yet been conducted with other CAR-engineered immune cells such as primary NK cells. This evidence concerns the gene KDR and melanoma.